AlzeCure Pharma announced that the company's presentation at the Alzheimer's conference AD/PD 2024, regarding new preclinical data with its leading clinical drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer's disease, is now available on the company's website. Data from the study show that ACD856 functions as a so-called biased PAM (positive allosteric modulator), i.e. that the substance potentiates certain signaling pathways but not others, which means that the substance can have potent effects and at the same time maintain a good safety profile. The results show that ACD856 can stimulate nerve cell growth, something that is important for communication between nerve cells.

In addition, the substance improves memory and learning ability in preclinical models. In contrast, pain signaling is not affected, which indicates a selective stimulation of specific signaling pathways. ACD856 is a Trk-PAM and enhances BDNF and NGF signaling, which among other things play an important role in normal nerve cell function and maintaining brain health.

The substance is under clinical development as a symptom-relieving treatment for disease states where the cognitive ability is impaired, for example in Alzheimer's disease. New preclinical data also suggest that ACD856 has potential protective and disease-modifying effects.